Brazil surpassed, on Friday, the 145 thousand deaths (145,388) by covid-19, after counting 708 deaths in the last 24 hours. Totals 4,880,523 infected, with 33,431 new infections
–
CoronaVac thus joins the vaccine developed by the pharmaceutical company AstraZeneca in collaboration with the University of Oxford, which has been under analysis at Anvisa since Thursday.
“Now, the Agency already has the first data on two vaccines. It is important to note that, at the moment, there is no conclusion on the quality, safety and efficacy of any of the two vaccines, which continue to comply with the third stage of testing. Submission Continuous is a differentiated procedure to speed up the analysis of data related to vaccines against covid-19 to be registered in the country “, added the regulator.
On Wednesday, the governor of São Paulo, the Brazilian state most affected by covid-19, signed a contract to receive 46 million doses of the CoronaVac vaccine and that it plans to apply it to the population as of December 15.
The agreement for 46 million vaccines against the new coronavirus, equivalent to the entire population of the state, was signed by the state governor, João Doria, by the director of the Butantan Institute, Dimas Covas, and by the world vice president of Sinovac, Weining Meng .
In the amount of US $ 90 million (76.8 million euros, current exchange rate), the contract also formalizes the transfer of technology for vaccine production by the Butantan Institute.
João Doria hopes that, once approved by the Brazilian health authorities, the vaccination campaign will start on December 15, with health professionals from São Paulo being the first to be immunized.
According to the São Paulo executive, the safety of the immunizer has already been proven in an investigation with more than 50,000 volunteers in China.
The vaccine is also being tested in Brazil since July and, currently, clinical studies of the last phase are followed by 12 scientific research centers in five Brazilian states and the Federal District.
The director of the Butatan Institute informed that seven thousand of the 13 thousand volunteers scheduled for this third and last phase of the tests, which will continue in Brazil until October 15, have already received the vaccine.
– .
